comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-14 21:58:09 - browse：19

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Medicare Advantage's lean provider networks lead CMS complaints

leisure time

explore

WSS

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Scientific mystery highlights the blind spots in genomics databases

Stopping antidepressants leads to symptoms for 1 in 6 patients

Multiple sclerosis has subtypes with different best treatments: study

Take antibiotics after sex, CDC recommends for certain risk groups

FDA approves Moderna’s RSV vaccine, its second licensed product

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

United colonoscopy coverage change 'may cost lives,' doctors say

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Researchers test human milk's ability to repair gut microbiome

Tori Bowie and the unacceptable rates of Black maternal death

Finland to offer bird flu vaccine to select groups of people, a possible global first

At least 13 dead in Texas as scorching temps continue

Young boy dies in trial for Pfizer Duchenne gene therapy

explore

Take antibiotics after sex, CDC recommends for certain risk groups

Bird flu reported in person exposed to presumably infected cattle

Structure Therapeutics oral GLP

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Study: Black kids more likely to die after surgery than white kids

A new initiative will help leaders fight the next pandemic

leisure time

leisure time

explore

Wikipedia